Michel Fabbro

17PUBLICATIONS
94CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Pacific Peoples midwifery and paediatricsCancer geneticsChiropractic
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Apr 27, 2026
Unusual Case of Neuromeningeal Late Relapse of POLE Mutated Endometrioid Carcinoma: A Case Report and Systematic Review.

|Jan 08, 2026
ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial.

Félix Blanc-Durand, Catherine Genestie, Sergey Nikolaev

|Aug 26, 2025
Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial.

Florence Joly, Alexandra Leary, Isabelle Ray-Coquard

|May 12, 2025
Integrated early palliative care for patients with newly diagnosed glioblastoma: The GLIOSUPPORT feasibility study.

Michel Fabbro, Muriel Thomaso, Amélie Darlix

|Jun 04, 2024
Author Correction: Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group.

Gilles Freyer, Anne Floquet, Olivier Tredan

|Apr 26, 2024
Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy.

Elisa Yaniz-Galende, Qinghe Zeng, Juan F Bejar-Grau

Pageof 3

Frequent Collaborators

4 joint publications

Frédéric Selle

4 joint publications

Jérôme Solassol

3 joint publications

Alexandra Leary

3 joint publications

Isabelle Ray-Coquard